JP6953400B2 - システイン反応性プローブとその使用 - Google Patents

システイン反応性プローブとその使用 Download PDF

Info

Publication number
JP6953400B2
JP6953400B2 JP2018516113A JP2018516113A JP6953400B2 JP 6953400 B2 JP6953400 B2 JP 6953400B2 JP 2018516113 A JP2018516113 A JP 2018516113A JP 2018516113 A JP2018516113 A JP 2018516113A JP 6953400 B2 JP6953400 B2 JP 6953400B2
Authority
JP
Japan
Prior art keywords
cysteine
protein
small molecule
containing protein
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018516113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501363A (ja
JP2019501363A5 (fr
Inventor
エフ． クラバット，ベンジャミン
エフ． クラバット，ベンジャミン
エム． バッカス，ケリアン
エム． バッカス，ケリアン
イー． コレイア，ブルーノ
イー． コレイア，ブルーノ
エム． ブルーエット，メーガン
エム． ブルーエット，メーガン
アール． テイジャロ，ジョン
アール． テイジャロ，ジョン
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2019501363A publication Critical patent/JP2019501363A/ja
Publication of JP2019501363A5 publication Critical patent/JP2019501363A5/ja
Application granted granted Critical
Publication of JP6953400B2 publication Critical patent/JP6953400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01042—Isocitrate dehydrogenase (NADP+) (1.1.1.42)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01023—Protein-arginine N-methyltransferase (2.1.1.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22061—Caspase-8 (3.4.22.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22063—Caspase-10 (3.4.22.63)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018516113A 2015-10-22 2016-10-21 システイン反応性プローブとその使用 Active JP6953400B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562244881P 2015-10-22 2015-10-22
US62/244,881 2015-10-22
US201662345710P 2016-06-03 2016-06-03
US62/345,710 2016-06-03
PCT/US2016/058308 WO2017070611A1 (fr) 2015-10-22 2016-10-21 Sondes réactives à la cystéine et utilisations associées

Publications (3)

Publication Number Publication Date
JP2019501363A JP2019501363A (ja) 2019-01-17
JP2019501363A5 JP2019501363A5 (fr) 2020-01-30
JP6953400B2 true JP6953400B2 (ja) 2021-10-27

Family

ID=58558160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516113A Active JP6953400B2 (ja) 2015-10-22 2016-10-21 システイン反応性プローブとその使用

Country Status (5)

Country Link
US (2) US10670605B2 (fr)
EP (1) EP3365686A4 (fr)
JP (1) JP6953400B2 (fr)
CA (1) CA3001847A1 (fr)
WO (1) WO2017070611A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10782295B2 (en) 2013-08-13 2020-09-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
CA3001847A1 (fr) 2015-10-22 2017-04-27 The Scripps Research Institute Sondes reactives a la cysteine et utilisations associees
EP3458445B1 (fr) 2016-05-18 2021-02-17 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
WO2017210600A1 (fr) * 2016-06-03 2017-12-07 The Scripps Research Institute Compositions et méthodes de modulation de réponse immunitaire
CA3050260A1 (fr) 2017-01-18 2018-07-26 The Scripps Research Institute Ligands photoreactifs et utilisations
WO2018144869A1 (fr) * 2017-02-03 2018-08-09 The Regents Of The University Of California Compositions et procédés de modulation d'uba5
CN110461322A (zh) * 2017-02-03 2019-11-15 加利福尼亚大学董事会 用于抑制浆膜蛋白4的组合物和方法
AU2018215448A1 (en) * 2017-02-03 2019-08-08 The Regents Of The University Of California Compositions and methods for modulating PPP2R1A
US20200278355A1 (en) * 2017-09-27 2020-09-03 The Scripps Research Institute Conjugated proteins and uses thereof
WO2019067733A1 (fr) * 2017-09-27 2019-04-04 Vividion Therapeutics, Inc. Composés et procédés de modulation de la dégradation protéique
WO2019075386A1 (fr) 2017-10-13 2019-04-18 The Regents Of The University Of California Modulateurs de mtorc1
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
SG11202004427TA (en) 2017-11-15 2020-06-29 Mirati Therapeutics Inc Kras g12c inhibitors
WO2019113724A1 (fr) * 2017-12-11 2019-06-20 广州君赫生物科技有限公司 Nouvelle application de disulfirame
WO2019217307A1 (fr) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
EP3908283A4 (fr) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
EP4021444A4 (fr) 2019-08-29 2023-01-04 Mirati Therapeutics, Inc. Inhibiteurs de kras g12d
KR20220091480A (ko) 2019-09-24 2022-06-30 미라티 테라퓨틱스, 인크. 병용 요법
JP2022552256A (ja) * 2019-10-15 2022-12-15 ジュニャーナ セラピューティクス インコーポレイテッド 反応性アフィニティプローブ相互作用探索プラットフォーム
WO2021076703A1 (fr) * 2019-10-16 2021-04-22 Vividion Therapeutics, Inc. Composés et procédés de modulation de protéines immunitaires
EP4045050A4 (fr) * 2019-10-16 2023-11-08 The Scripps Research Institute Carte de guide d'activité d'interactions électrophile-cystéine dans des cellules immunitaires humaines primaires
CN111063389B (zh) * 2019-12-04 2021-10-29 浙江工业大学 一种基于深度卷积神经网络的配体绑定残基预测方法
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
CN112255396A (zh) * 2020-10-15 2021-01-22 南开大学 一种测量小分子药物抑制蛋白核酸互作的单分子力学方法
WO2022240966A1 (fr) * 2021-05-11 2022-11-17 Opna Immuno-Oncology Sa Composés et procédés de modulation yap-tead et leurs indications
WO2023092133A1 (fr) * 2021-11-22 2023-05-25 The Scripps Research Institute Ligands covalents stéréosélectifs pour des protéines oncogènes et immunologiques
WO2024059575A2 (fr) * 2022-09-12 2024-03-21 Arizona Board Of Regents On Behalf Of The University Of Arizona Composition, dispositif, système et procédés pour détecter des toxiques environnementaux
WO2024073486A2 (fr) * 2022-09-28 2024-04-04 The General Hospital Corporation Sondes et procédés pour identifier des sites d'acylation de graisses ligandables pour l'identification de cibles thérapeutiques
CN116790698B (zh) * 2023-06-21 2024-06-18 南京大学 基于氧化脱羧酶的硫醛合成方法及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
JP2003502036A (ja) * 1999-06-10 2003-01-21 ファルマシア・アンド・アップジョン・カンパニー カスパーゼ−８の結晶、モデルおよび方法
DE60137356D1 (de) * 2000-11-21 2009-02-26 Sunesis Pharmaceuticals Inc Erweiterter "tethering" ansatz zum schnellen auffinden von liganden
WO2005118833A2 (fr) 2004-06-01 2005-12-15 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour des maladies associees a une kinase a motif sterile-alpha et a motif de type glissiere a leucine (zak)
US7935479B2 (en) 2004-07-19 2011-05-03 Cell Biosciences, Inc. Methods and devices for analyte detection
JPWO2008029924A1 (ja) * 2006-09-08 2010-01-21 大日本住友製薬株式会社 環状アミノアルキルカルボキサミド誘導体
JP2010505868A (ja) 2006-10-02 2010-02-25 ザ スクリプス リサーチ インスティチュート エーテル脂質シグナル伝達経路を制御する酵素
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
EP1947193A1 (fr) 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Procédé de criblage pour composés antidiabétiques
WO2008109997A1 (fr) * 2007-03-09 2008-09-18 The University Of British Columbia Ciblage de maladie à médiation de la pro-caspase-8
WO2013192364A1 (fr) * 2012-06-22 2013-12-27 The University Of Vermont And State Agricultural College Traitements d'états de stress oxydatif
WO2014197471A1 (fr) 2013-06-03 2014-12-11 Acetylon Pharmaceuticals, Inc. Biomarqueurs de histone-désacétylase (hdac) dans un myélome multiple
US10782295B2 (en) 2013-08-13 2020-09-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
JP2017528448A (ja) 2014-08-21 2017-09-28 エスアールエックス カーディオ，エル エル シー プロタンパク質コンバターゼであるスブチリシン／ケキシンタイプ９（ｐｃｓｋ９）のタンパク質活性のモジュレーションのための、結合リガンドとしての小分子の組成物およびその使用方法
CA3001847A1 (fr) 2015-10-22 2017-04-27 The Scripps Research Institute Sondes reactives a la cysteine et utilisations associees
CA3050260A1 (fr) 2017-01-18 2018-07-26 The Scripps Research Institute Ligands photoreactifs et utilisations

Also Published As

Publication number Publication date
US20170115303A1 (en) 2017-04-27
EP3365686A4 (fr) 2019-03-27
JP2019501363A (ja) 2019-01-17
US10670605B2 (en) 2020-06-02
US20200292555A1 (en) 2020-09-17
CA3001847A1 (fr) 2017-04-27
WO2017070611A1 (fr) 2017-04-27
EP3365686A1 (fr) 2018-08-29

Similar Documents

Publication Publication Date Title
JP6953400B2 (ja) システイン反応性プローブとその使用
Ward et al. Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications
US10859585B2 (en) Lipid probes and uses thereof
Ulrich et al. Ubiquitin signalling in DNA replication and repair
Thinon et al. N-myristoyltransferase inhibition induces ER-stress, cell cycle arrest, and apoptosis in cancer cells
Prieto et al. Large-scale differential proteome analysis in Plasmodium falciparum under drug treatment
US20220214355A1 (en) Sulfur-heterocycle exchange chemistry and uses thereof
Fan et al. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling
US20200071277A1 (en) Photoreactive ligands and uses thereof
US20210255193A1 (en) Lysine reactive probes and uses thereof
CA3195950A1 (fr) Composes pour la degradation ciblee de proteines de kinases
Teng et al. Development of PDE6D and CK1α degraders through chemical derivatization of FPFT-2216
US20200278355A1 (en) Conjugated proteins and uses thereof
Gunasekaran et al. Development of a polo-like kinase-1 polo-box domain inhibitor as a tumor growth suppressor in mice models
Lu et al. Discovery of the first examples of threonine tyrosine kinase PROTAC degraders
Xie et al. Development of potent and selective coactivator-associated arginine methyltransferase 1 (CARM1) degraders
Zhou et al. Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D
Harding et al. Discovery and characterization of a chemical probe targeting the zinc-finger ubiquitin-binding domain of HDAC6
Zhou et al. Degradation of rat sarcoma proteins targeting the post-translational prenyl modifications via cascade azidation/fluorination and click reaction
Lv et al. Cyclopropenone, cyclopropeniminium ion, and cyclopropenethione as novel electrophilic warheads for potential target discovery of triple-negative breast cancer
Kumar et al. Chemically targeting the redox switch in AP1 transcription factor ΔFOSB
US20240123078A1 (en) Compounds and methods for modulating immune-related proteins
King Utilizing Proteolysis-Targeting Chimeras to Target the Transcriptional Cyclin-Dependent Kinases 9 and 12
Pei et al. Exploring Protein S-Palmitoylation: Mechanisms, Detection, and Strategies for Inhibitor Discovery
Withers-Martinez et al. Peptidic Boronic Acid Plasmodium falciparum SUB1 Inhibitors with Improved Selectivity over Human Proteasome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210929

R150 Certificate of patent or registration of utility model

Ref document number: 6953400

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250